These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 12477503

  • 21. Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome.
    Ludwig M, Bauer O, Lopens A, Jelkmann W, Diedrich K.
    Hum Reprod; 1998 Jan; 13(1):30-2. PubMed ID: 9512224
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Preliminary study on the role of vascular endothelial growth factor in pathogenesis of ovarian hyperstimulation syndrome].
    Zhou C, Yu C, Zhuang G.
    Zhonghua Fu Chan Ke Za Zhi; 2001 Nov; 36(11):654-6. PubMed ID: 11930688
    [Abstract] [Full Text] [Related]

  • 24. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
    Rizk B, Aboulghar M, Smitz J, Ron-El R.
    Hum Reprod Update; 1997 Nov; 3(3):255-66. PubMed ID: 9322101
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report.
    Krasnow JS, Berga SL, Guzick DS, Zeleznik AJ, Yeo KT.
    Fertil Steril; 1996 Mar; 65(3):552-5. PubMed ID: 8774285
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome.
    Chen CD, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS.
    Hum Reprod; 2000 Jan; 15(1):66-71. PubMed ID: 10611190
    [Abstract] [Full Text] [Related]

  • 30. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
    Jellad S, Haj Hassine A, Basly M, Mrabet A, Chibani M, Rachdi R.
    J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P.
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T.
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [Abstract] [Full Text] [Related]

  • 36. The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome.
    Kobayashi H, Okada Y, Asahina T, Gotoh J, Terao T.
    J Mol Endocrinol; 1998 Jun; 20(3):363-74. PubMed ID: 9687159
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The effects of 'coasting' on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome.
    Tozer AJ, Iles RK, Iammarrone E, Gillott CM, Al-Shawaf T, Grudzinskas JG.
    Hum Reprod; 2004 Mar; 19(3):522-8. PubMed ID: 14998945
    [Abstract] [Full Text] [Related]

  • 40. [Relationship between letrozole administration during the luteal phase after oocyte retrieval and the early-stage ovarian hyperstimulation syndrome oocurrence].
    He Q, Xu J, Cui S, Li H, Zhang C.
    Zhonghua Fu Chan Ke Za Zhi; 2014 Dec; 49(12):909-13. PubMed ID: 25608991
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.